Desmin 370 (Opocrin SpA/Alfa Wassermann)

Alfa Wassermann, in collaboration with Opocrin, is developing Desmin 370, an antithrombotic agent which is in phase III clinical trials for the treatment of deep vein thrombosis, and may have potential in the treatment of pulmonary embolism. The antithrombotic effect is attributed to the inhibition of thrombin generation, potentiation of heparin cofactor II activity, and local fibrinolytic effects. Opocrin is the product patent holder (EP-00221977 and US-04973580), while Alfa Wassermann is the developer and responsible for the clinical research.